Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- 26 May 2023
- journal article
- review article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 62 (2) , 106870
Abstract
No abstract availableKeywords
Funding Information
- Sichuan Provincial Science and Technology Support Program (2023JDR0246)
- Sichuan Provincial Science and Technology Support Program (2022JDR0326)
This publication has 32 references indexed in Scilit:
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsNew England Journal of Medicine, 2021
- RdRp inhibitors and COVID-19: Is molnupiravir a good option?Biomedicine & Pharmacotherapy, 2021
- Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral CorrelatesClinical Infectious Diseases, 2021
- Molnupiravir—A Novel Oral Anti-SARS-CoV-2 AgentAntibiotics, 2021
- Structural biology of SARS-CoV-2 and implications for therapeutic developmentNature Reviews Microbiology, 2021
- Non-Nucleotide RNA-Dependent RNA Polymerase Inhibitor That Blocks SARS-CoV-2 ReplicationViruses, 2021
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)Nature Reviews Drug Discovery, 2020
- Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of InterventionsCochrane Database of Systematic Reviews, 2019
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- A basic introduction to fixed-effect and random-effects models for meta-analysisResearch Synthesis Methods, 2010